Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

NIH 2OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Lymphoid 39Other hematologic neoplasm 33CNS 18Thoracic 17Breast 17Gastrointestinal 15Plasma cell 12Myeloid 9Genitourinary 9Dermatologic 9Sarcoma 6Gynecologic 6Head & Neck 5Other solid neoplasm 4Classical hematology 3Tumor-Agnostic 1Endocrine 1

Conditions

Pheochromocytoma 1Paraganglioma 1Neuroblastoma 1

Interventions

lutetium Lu 177 dotatate 36Everolimus 32pembrolizumab 24Temozolomide 21Magnetic Resonance Spectroscopy 21Nivolumab 18lenvatinib 17gallium Ga 68 dotatate 16cabozantinib 15Cisplatin 15lanreotide 143-Iodobenzylguanidine 14Capecitabine 13trametinib 12dabrafenib 12Bevacizumab 12Octreotide 11Surveys and Questionnaires 10Surgical Procedures, Operative 10Sunitinib 10Radiosurgery 10Positron Emission Tomography Computed Tomography 10Blood Specimen Collection 10Sorafenib 9Paclitaxel 9Ipilimumab 9Carboplatin 9surufatinib 8Etoposide 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Vorinostat × Endocrine × Clear all
NCT01838187 2023-08-18

Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Children's Hospital Medical Center, Cincinnati

No longer available
CNSEndocrine

Neuroblastoma, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡